Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore implemented a detailed, prospective, clinical cardiac and renal evaluation of 62 Cfz-treated myeloma patients, including serial blood pressure (BP), c...

Full description

Saved in:
Bibliographic Details
Published in:Blood Cancer J
Main Authors: Rosenthal, A, Luthi, J, Belohlavek, M, Kortüm, K M, Mookadam, F, Mayo, A, Fonseca, R, Bergsagel, P L, Reeder, C B, Mikhael, J R, Stewart, A K
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2016
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4742629/
https://ncbi.nlm.nih.gov/pubmed/26771810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2015.112
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items